Unveiling 5 Analyst Insights On Editas Medicine
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 25.93% decrease from the previous average price target of $13.50.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light on the perception of Editas Medicine by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jay Olson | Oppenheimer | Maintains | Perform | $12.00 | $12.00 |
| Liisa Bayko | Evercore ISI Group | Lowers | In-Line | $7.00 | $15.00 |
| Samantha Semenkow | Citigroup | Lowers | Buy | $15.00 | $16.00 |
| Matthew Harrison | Morgan Stanley | Announces | Equal-Weight | $7.00 | - |
| Gena Wang | Barclays | Lowers | Equal-Weight | $9.00 | $11.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Editas Medicine. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Editas Medicine compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Editas Medicine's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Editas Medicine's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Editas Medicine analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Breaking Down Editas Medicine's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Editas Medicine's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -88.48%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Editas Medicine's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5458.15% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Editas Medicine's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -19.25%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Editas Medicine's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.19%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Editas Medicine's debt-to-equity ratio is below the industry average. With a ratio of 0.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.